The OptiZest study aims to investigate individualized doses of Zestril for these patients.
Closed Loop Medicine and Pharmanovia announces the launch of a new study and patient recruitment to investigate precision medicine combination therapy in patients with hypertension.
The OptiZest study, supported by the National Institute for Health and Care Excellence, will investigate whether personalized doses of Zestril (lisinopril) can help improve blood pressure control in people with high blood pressure at home.
This announcement builds on the companies’ ongoing joint development partnership. announced In May 2023, Pharmavia’s pharmaceutical brands will be combined with closed-loop technology to deliver dose-optimized, personalized treatments.
Hypertension, a disease that affects one in four men and one in five women, occurs when blood pressure in the blood vessels is too high.
In an effort to advance the development and launch of a combination drug and software version of a first-line antihypertensive drug in the UK, the study comprises a closed-loop proprietary software-as-a-medical-device (SaMD) dose optimization technology. Pharmanovia is a pharmaceutical brand established to develop innovative interventions for patients and healthcare professionals.
Based on recent trial data, the SaMD platform has already demonstrated the ability to adequately control blood pressure, minimize side effects, and support patient medication adherence in addition to other first-line antihypertensive medications. I am.
Dr. Hakim Yadi, CEO and co-founder of Closed Loop, commented: “The OptiZest research…is not only a milestone in hypertension management, but also underscores our broader mission to help health systems improve patient outcomes across diverse treatment areas. ”
Dr. James Burt, Chief Executive Officer of Pharmanovia, said: “This research begins by providing much-needed innovation in hypertension management and is the first drug-software combination product for hypertension. “This will prepare us to develop and launch one.”
Closed loop in February 2024 share The company’s personalized hypertension treatment drug CLM-HT01 achieved positive results in the PERSONAL-COVIDBP clinical trial. Journal of the American Heartcontrol blood pressure while minimizing side effects and supporting medical adherence in patients living with this condition.
